$IFRX News

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

InflaRx Mulls Feasibility For AAV In Europe

What Do Analysts Say About InflaRx N.V. (IFRX)?

Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now

Raymond James Upgrades InflaRx to Strong Buy, Raises Price Target to $9

HC Wainwright & Co. Maintains Buy on InflaRx, Raises Price Target to $8

Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $4

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript

InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases - Slideshow

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx N.V. (IFRX) Regains Compliance With Nasdaq

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

InflaRx Prices Underwritten Offering of 75M Shares At $2.00 Per Share

InflaRx Announces That It Intends To Develop Izicopan, An Oral C5A Receptor Inhibitor, In Life-Threatening Kidney Disorder AAV

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

InflaRx to Report First Quarter 2026 Results on May 7, 2026

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

InflaRx Regains Nasdaq Compliance